Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's president and CEO, Raul Rodriguez, will deliver a company overview on Thursday, January 16, 2025, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco.

The presentation will be accessible via live webcast through the Investor Relations section of Rigel's website. Founded in 1996 and headquartered in South San Francisco, California, Rigel focuses on discovering, developing, and providing innovative therapies for patients with hematologic disorders and cancer.

01/08/2025 - 08:05 AM

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com

Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345248.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When is Rigel Pharmaceuticals (RIGL) presenting at the J.P. Morgan Healthcare Conference 2025?

Rigel Pharmaceuticals will present on Thursday, January 16, 2025, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco.

How can investors access Rigel's (RIGL) J.P. Morgan Healthcare Conference presentation?

Investors can access the live webcast or archived recording through the Investor Relations section of Rigel's website at www.rigel.com.

What is Rigel Pharmaceuticals' (RIGL) main business focus?

Rigel Pharmaceuticals is a commercial stage biotechnology company focused on hematologic disorders and cancer, dedicated to discovering, developing, and providing novel therapies.